Guardant Deferred Long Term Liab from 2010 to 2024

GH Stock  USD 35.40  2.75  8.42%   
Guardant Health's Deferred Long Term Liabilities is decreasing with slightly volatile movements from year to year. Deferred Long Term Liabilities is predicted to flatten to about 6.3 M. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2010-12-31
Previous Quarter
7.1 M
Current Value
6.3 M
Quarterly Volatility
439.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Guardant Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Guardant Health's main balance sheet or income statement drivers, such as Tax Provision of 719.2 K, Net Interest Income of 34.4 M or Interest Income of 37.1 M, as well as many indicators such as Price To Sales Ratio of 5.1, Dividend Yield of 0.0022 or PTB Ratio of 13.78. Guardant financial statements analysis is a perfect complement when working with Guardant Health Valuation or Volatility modules.
  
Check out the analysis of Guardant Health Correlation against competitors.
For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.

Currently Active Assets on Macroaxis

Check out the analysis of Guardant Health Correlation against competitors.
For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.28)
Revenue Per Share
5.7
Quarterly Revenue Growth
0.339
Return On Assets
(0.16)
Return On Equity
(6.09)
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.